The March 2026 quarter results paint a sobering picture of a company struggling to achieve operational viability. Despite a sequential revenue increase of 46.87% to ₹0.47 crores, the company's cost structure remains fundamentally misaligned, with employee costs alone reaching ₹0.96 crores—more than double the quarterly revenue. This structural imbalance has resulted in operating losses that continue to widen, with the operating profit margin deteriorating to negative 204.26% in Q4 FY26 from negative 512.50% in the previous quarter.
The stock's precipitous decline following the results announcement reflects growing investor scepticism about management's ability to execute a credible turnaround strategy. Trading below all major moving averages and having surrendered 30.24% from its 52-week high of ₹93.96, Relic Technologies finds itself in a precarious position with limited institutional support—just 0.02% mutual fund holding and no foreign institutional investor presence whatsoever.
| Quarter | Revenue (₹ Cr) | QoQ Change | Net Profit (₹ Cr) | QoQ Change | Operating Margin |
|---|---|---|---|---|---|
| Mar'26 | 0.47 | +46.87% | -2.01 | +617.86% | -204.26% |
| Dec'25 | 0.32 | -46.67% | -0.28 | -275.00% | -512.50% |
| Sep'25 | 0.60 | -53.12% | 0.16 | -104.35% | -143.33% |
| Jun'25 | 1.28 | +172.34% | -3.68 | +736.36% | -111.72% |
| Mar'25 | 0.47 | 0.00% | -0.44 | -56.00% | -65.96% |
| Dec'24 | 0.47 | -25.40% | -1.00 | -814.29% | -204.26% |
| Sep'24 | 0.63 | — | 0.14 | — | 26.98% |
Financial Performance: A Crisis of Profitability
The fourth quarter of FY26 exposed the fundamental fragility of Relic Technologies' business model. Net sales of ₹0.47 crores, whilst representing a 46.87% sequential improvement from December 2025's ₹0.32 crores, remained stubbornly flat on a year-over-year basis. More concerning is the company's inability to generate sustainable revenue growth despite being a National Stock Exchange member with institutional clients in the share broking segment.
The cost structure tells a particularly troubling story. Employee costs surged to ₹0.96 crores in Q4 FY26, up from ₹1.26 crores in the previous quarter but representing a staggering 204.26% of quarterly revenue. This fundamental mismatch between revenue generation and fixed costs has resulted in an operating loss of ₹0.96 crores before other income, translating to an operating margin of negative 204.26%. Even after accounting for other income of ₹0.19 crores, the company posted an operating loss of ₹0.77 crores.
The bottom line deterioration accelerated dramatically in the March quarter. After tax adjustments that added ₹2.06 crores to losses—reflecting a bizarre negative tax rate of 236.78%—the company reported a standalone net loss of ₹2.94 crores and a consolidated net loss of ₹2.01 crores. This represents a catastrophic 617.86% sequential deterioration and a 356.82% year-over-year worsening, underscoring the absence of any meaningful operational improvement.
0.00% YoY
▼ 356.82% YoY
Operational Challenges: The Cost Structure Conundrum
The most glaring issue facing Relic Technologies is its inability to align costs with revenue generation capacity. With employee costs consistently exceeding total revenue, the company finds itself trapped in a structural loss-making position that shows no signs of resolution. The Q4 FY26 employee cost of ₹0.96 crores against revenue of ₹0.47 crores represents a fundamental business model failure that cannot be sustained indefinitely.
Return on equity metrics paint an equally bleak picture. The latest ROE stands at negative 15.24%, whilst the average ROE over recent periods registers at just 3.74%—far below the threshold required for value creation. This weak capital efficiency reflects the company's inability to generate adequate returns on shareholder funds, which stood at ₹9.84 crores as of March 2025. The return on capital employed (ROCE) tells a similar story, with the latest reading at negative 29.61%, indicating that the company is destroying capital rather than creating it.
Balance sheet quality remains relatively stable, with net debt-to-equity at a manageable 0.25 and current assets of ₹7.76 crores providing some cushion against current liabilities of ₹2.90 crores. Fixed assets increased to ₹2.58 crores from ₹0.99 crores in the previous year, suggesting some capital investment, though the returns on these investments remain conspicuously absent.
Critical Red Flag: Unsustainable Cost Structure
Employee costs of ₹0.96 crores exceeded quarterly revenue of ₹0.47 crores by 104%, creating a structural loss-making position that threatens the company's viability. With operating margins at negative 204.26% and no clear path to profitability, investors face significant risk of permanent capital loss. The company's contemplated diversification into pharmaceutical activities appears more aspirational than actionable given current financial constraints.
The Share Broking Struggle: Industry Headwinds Mount
Relic Technologies operates in the highly competitive share broking industry, where scale advantages and technology capabilities increasingly determine success. As a small player with institutional clients, the company faces formidable challenges from larger, better-capitalised competitors who can offer superior technology platforms, research capabilities, and pricing.
The company's stated intention to diversify into pharmaceutical activities through a potential name change to Relic Life Science Ltd. raises more questions than it answers. With current operations generating substantial losses and limited financial resources, the strategic rationale and execution capability for such a dramatic pivot remain unclear. Investors should view this diversification plan with considerable scepticism given the company's inability to achieve profitability in its core broking business.
Market dynamics in the broking industry have shifted dramatically towards discount brokers and technology-enabled platforms, leaving traditional brokers struggling for relevance. Relic Technologies' stagnant revenue base suggests it has failed to adapt to these changing industry dynamics, raising questions about management's strategic vision and execution capabilities.
Peer Comparison: Trailing the Competition
When benchmarked against peers in the NBFC sector, Relic Technologies' underperformance becomes starkly apparent. The company's average ROE of 3.74% lags behind peers such as Kalyan Capitals (8.65%) and Anupam Finserv (6.38%), reflecting inferior capital efficiency and profitability.
| Company | P/E (TTM) | Price/Book | ROE (%) | Debt/Equity |
|---|---|---|---|---|
| Relic Technologies | NA (Loss Making) | 3.71x | 3.74% | 0.25 |
| Kalyan Capitals | 12.33x | 0.90x | 8.65% | 4.85 |
| Ajcon Global | NA (Loss Making) | 1.53x | 4.97% | 0.37 |
| BSEL ALGO | 40.25x | 0.08x | 4.37% | 0.00 |
| Anupam Finserv | 24.01x | 1.40x | 6.38% | 0.11 |
Perhaps most concerning is Relic Technologies' valuation disconnect. Despite being loss-making with deteriorating fundamentals, the stock trades at a price-to-book ratio of 3.71x—substantially higher than most profitable peers. This valuation premium lacks fundamental justification and suggests significant downside risk as reality catches up with market pricing. The peer average P/BV of approximately 1.70x implies Relic Technologies trades at more than double the valuation multiple despite inferior operational performance.
Valuation Analysis: Expensive for a Loss-Maker
Relic Technologies' valuation metrics flash warning signals across the board. With the company firmly in loss-making territory, traditional earnings-based multiples like P/E ratio are meaningless. However, the price-to-book ratio of 3.71x stands out as particularly egregious given the negative returns on equity and deteriorating financial performance.
The EV/EBITDA multiple of negative 7.45x and EV/EBIT of negative 6.85x reflect the company's loss-making status, whilst the EV/Sales ratio of 11.82x suggests the market is pricing in a miraculous turnaround that current fundamentals do not support. With an enterprise value significantly exceeding sustainable revenue generation capacity, the stock appears fundamentally overvalued by any reasonable metric.
The proprietary Mojo Score of just 17 out of 100 reflects the confluence of negative factors: risky valuation, below-average quality, flat financial trends, and bearish technical indicators. The stock's classification as "RISKY" in valuation terms appears entirely justified given the operational challenges and lack of profitability visibility.
Shareholding Pattern: Promoters Hold Steady Amid Turmoil
The shareholding structure reveals a promoter-dominated company with minimal institutional interest. Promoter holding stood at 44.93% as of March 2026, registering a marginal 0.15% sequential increase from 44.78% in December 2025. This follows a more significant 1.77% decline in the previous quarter, suggesting some volatility in promoter shareholding patterns.
| Quarter | Promoter | QoQ Change | FII | Mutual Funds | Non-Institutional |
|---|---|---|---|---|---|
| Mar'26 | 44.93% | +0.15% | 0.00% | 0.02% | 55.05% |
| Dec'25 | 44.78% | -1.77% | 0.00% | 0.02% | 55.20% |
| Sep'25 | 46.55% | 0.00% | 0.00% | 0.02% | 53.43% |
| Jun'25 | 46.55% | 0.00% | 0.00% | 0.02% | 53.43% |
The complete absence of foreign institutional investors and negligible mutual fund holding of just 0.02% speaks volumes about institutional sentiment. With 55.05% held by non-institutional investors, the stock remains primarily in retail hands—a concerning dynamic given the company's deteriorating fundamentals and lack of professional investor validation. Positively, no promoter shares are pledged, eliminating one potential risk factor in an otherwise challenging situation.
Stock Performance: Brutal Selloff Accelerates Downtrend
The stock's price action following the Q4 FY26 results announcement reflects growing investor disillusionment. The 13.64% single-day decline to ₹65.55 pushed shares below all major moving averages, with the stock now trading 14.90% above its 52-week low of ₹57.05 but a painful 30.24% below its 52-week high of ₹93.96.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | -6.78% | +0.24% | -7.02% |
| 1 Month | -15.16% | -3.95% | -11.21% |
| 3 Months | -18.97% | -8.93% | -10.04% |
| YTD | -16.74% | -11.51% | -5.23% |
| 1 Year | -12.19% | -6.84% | -5.35% |
| 2 Years | +305.88% | +1.61% | +304.27% |
| 3 Years | +187.50% | +21.71% | +165.79% |
Short-term performance metrics reveal consistent underperformance across all recent timeframes. The stock has declined 6.78% over the past week, 15.16% over one month, and 18.97% over three months—substantially underperforming the Sensex in each period. The one-year return of negative 12.19% compares unfavourably to the Sensex decline of 6.84%, resulting in negative alpha of 5.35%.
Longer-term returns tell a different story, with the stock delivering exceptional gains over two-year (305.88%), three-year (187.50%), and five-year (410.91%) periods. However, these historical returns increasingly appear disconnected from current operational realities, suggesting early investors who capitalised on speculative momentum rather than fundamental improvement.
Technical indicators uniformly point to continued weakness. The stock trades in a "mildly bearish" trend as of May 22, 2026, with MACD bearish on weekly and monthly timeframes, Bollinger Bands signalling bearish momentum weekly, and moving averages providing bearish signals. With a high beta of 1.50, the stock exhibits significantly greater volatility than the broader market—a characteristic that amplifies downside risk in the current negative trend.
Investment Thesis: Quality Concerns Dominate
The investment case for Relic Technologies rests on shaky foundations. The company's "below average" quality grade reflects weak long-term financial performance, with five-year EBIT growth at a disastrous negative 228.62% despite sales growth of 16.58%. This disconnect between top-line expansion and profitability deterioration underscores fundamental execution failures.
The Mojo 4 Dots analysis reveals uniformly negative signals. Near-term drivers register as "mixed" at best, with flat quarterly financial trends and mildly bearish technical momentum. Quality assessment remains "below average," reflecting the company's persistent inability to generate adequate returns on capital. Valuation sits firmly in "risky" territory, with stretched multiples unsupported by operational performance. The overall assessment of "mixed" appears generous given the preponderance of negative factors.
Key Strengths & Risk Factors
Limited Strengths ✓
- Low Leverage: Debt-to-equity of 0.25 provides financial flexibility and reduces bankruptcy risk
- No Promoter Pledging: Eliminates risk of forced selling or loss of control
- NSE Membership: Institutional infrastructure provides platform for potential recovery
- Positive Working Capital: Current assets of ₹7.76 crores exceed current liabilities, ensuring near-term liquidity
- Long-Term Returns: Historical three-year and five-year returns demonstrate past periods of strong performance
Critical Concerns ⚠️
- Structural Losses: Operating margins of negative 204.26% reflect fundamentally broken business model
- Cost Structure Crisis: Employee costs exceed revenue by 104%, creating unsustainable cash burn
- Negative ROE: Latest ROE of negative 15.24% indicates capital destruction rather than creation
- No Institutional Support: Negligible 0.02% institutional holding reflects lack of professional investor confidence
- Valuation Disconnect: P/BV of 3.71x unjustified for loss-making company with deteriorating fundamentals
- Weak Competitive Position: Stagnant revenue in growing industry suggests market share loss to larger competitors
- Diversification Risk: Proposed pharmaceutical pivot appears desperate rather than strategic given financial constraints
Outlook: What to Watch
Positive Catalysts (Remote Probability)
- Meaningful cost restructuring programme bringing employee costs below 50% of revenue
- Strategic partnership or acquisition providing scale and technology capabilities
- Successful diversification into pharmaceuticals with credible execution plan and funding
- Return to quarterly profitability with sustainable operating margins above 10%
Red Flags (High Probability)
- Continued quarterly losses exceeding ₹1.00 crore indicating no turnaround progress
- Further promoter stake reduction below 40% signalling loss of confidence
- Revenue declining below ₹0.40 crores quarterly, threatening viability
- Working capital deterioration requiring emergency fundraising at unfavourable terms
- Failure to articulate credible strategic plan within next two quarters
The Verdict: Avoid This Value Trap
Relic Technologies Ltd. represents a textbook example of a value trap—a stock that appears cheap on certain metrics but lacks the fundamental quality to justify even depressed valuations. The Q4 FY26 results have laid bare the structural challenges facing this micro-cap NBFC, with losses accelerating despite modest revenue growth and no credible path to profitability in sight.
The company's cost structure remains fundamentally misaligned with its revenue generation capacity, creating a cash burn dynamic that threatens long-term viability. Management's contemplated diversification into pharmaceuticals appears more aspirational than actionable given current financial constraints and execution track record. With negligible institutional support, deteriorating technical momentum, and valuation multiples that defy fundamental justification, the risk-reward equation tilts decisively negative.
Investment Verdict
Score: 17/100
For Fresh Investors: Avoid entirely. The company's structural loss-making position, negative returns on equity, and lack of credible turnaround strategy make this an unacceptable risk at any price. Better opportunities exist in the financial services sector with proven profitability and institutional backing.
For Existing Holders: Exit on any price recovery above ₹70. The 13.64% post-results decline reflects growing market recognition of fundamental challenges. With the stock trading at unjustified valuation premiums despite deteriorating operations, further downside appears likely as reality catches up with market pricing.
Fair Value Estimate: ₹35-40 (40-46% downside from current levels), reflecting book value discount appropriate for structurally unprofitable business with questionable long-term viability.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Investing in micro-cap stocks carries substantial risk of loss and may not be suitable for all investors.
